First Trust Direct Indexing L.P. Boosts Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

First Trust Direct Indexing L.P. grew its holdings in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 26.4% during the 3rd quarter, HoldingsChannel reports. The fund owned 1,635 shares of the biotechnology company’s stock after acquiring an additional 341 shares during the quarter. First Trust Direct Indexing L.P.’s holdings in Sarepta Therapeutics were worth $204,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Capital International Investors increased its stake in shares of Sarepta Therapeutics by 1.6% in the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock worth $623,676,000 after buying an additional 76,032 shares during the period. Farallon Capital Management LLC increased its stake in shares of Sarepta Therapeutics by 102.8% in the first quarter. Farallon Capital Management LLC now owns 2,453,500 shares of the biotechnology company’s stock worth $317,630,000 after buying an additional 1,243,427 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of Sarepta Therapeutics by 6.3% in the second quarter. Thrivent Financial for Lutherans now owns 644,675 shares of the biotechnology company’s stock worth $101,858,000 after buying an additional 37,940 shares during the period. Jacobs Levy Equity Management Inc. increased its stake in shares of Sarepta Therapeutics by 26.3% in the first quarter. Jacobs Levy Equity Management Inc. now owns 579,637 shares of the biotechnology company’s stock worth $75,040,000 after buying an additional 120,535 shares during the period. Finally, abrdn plc increased its stake in shares of Sarepta Therapeutics by 30.7% in the third quarter. abrdn plc now owns 431,098 shares of the biotechnology company’s stock worth $53,935,000 after buying an additional 101,253 shares during the period. 86.68% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. In related news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Michael Andrew Chambers bought 37,038 shares of Sarepta Therapeutics stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the completion of the acquisition, the director now directly owns 284,034 shares in the company, valued at $38,003,749.20. This represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Price Performance

NASDAQ SRPT opened at $125.01 on Wednesday. Sarepta Therapeutics, Inc. has a 52 week low of $75.85 and a 52 week high of $173.25. The firm has a market capitalization of $11.92 billion, a P/E ratio of 277.81 and a beta of 0.81. The company has a quick ratio of 3.19, a current ratio of 3.90 and a debt-to-equity ratio of 1.05. The company has a 50-day moving average price of $127.07 and a 200-day moving average price of $132.82.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, beating the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a net margin of 3.14% and a return on equity of 5.32%. The firm had revenue of $362.90 million during the quarter, compared to analyst estimates of $394.38 million. During the same quarter in the prior year, the firm earned ($0.27) EPS. The business’s revenue for the quarter was up 38.9% compared to the same quarter last year. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 1.48 earnings per share for the current year.

Analyst Ratings Changes

Several analysts recently weighed in on SRPT shares. UBS Group lifted their price target on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a report on Tuesday, September 17th. Raymond James reiterated an “outperform” rating and issued a $150.00 price target on shares of Sarepta Therapeutics in a report on Thursday, October 10th. William Blair upgraded shares of Sarepta Therapeutics to a “strong-buy” rating in a report on Friday, August 30th. Barclays cut their price target on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Finally, Piper Sandler cut their price target on shares of Sarepta Therapeutics from $205.00 to $200.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. Two research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $182.95.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.